Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 275 No 7380 p734
17 December 2005

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Social-value judgements not relevant to health care

Treatment should not be denied when conditions may be self-inflicted

Treatment should not be denied when conditions may be self-inflicted

Treatment should not be denied to patients with conditions that may be self-inflicted, the National Institute for Health and Clinical Excellence says in a report published last week. The report, “Social value judgements: principles for the development of NICE guidance”, describes the institute’s approach to incorporating social value judgements into the processes used to develop NICE guidance. It will be used only to help those developing NICE guidance and is not intended as guidance for the wider NHS.

There are two reasons why NICE should not take into account whether a condition is self-inflicted, says the report. First, it is often impossible to decide whether someone’s condition is self-inflicted or due to other factors, and secondly, it does not accept the principle of “deservedness” in priority setting within the NHS. However, if self-inflicted causes of the condition influence the clinical or cost-effectiveness of the intervention, it may be appropriate to take this into account, it adds. A spokeswoman for NICE gave the example of a patient with chronic obstructive pulmonary disease who needs oxygen therapy and is a smoker. “The effect of the smoking means that oxygen therapy is dangerous and can lead to an explosion,” she says.

The report also emphasises that socioeconomic status, gender and sexual orientation should not influence access to treatment. It adds that age and race should only influence access when there is clear evidence that these cause differences in the clinical effectiveness of an intervention.

Patient choice is also addressed: “While respect for autonomy and individual choice are important for the NHS and its users, this should not have the consequence of disadvantaging NHS users as a whole by having an unacceptable opportunity cost or promoting the use of interventions that are clinically and/or cost ineffective.”

Back to Top


©The Pharmaceutical Journal